
Sign up to save your podcasts
Or
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
4.5
304304 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
30,845 Listeners
1,040 Listeners
1,789 Listeners
478 Listeners
122 Listeners
84 Listeners
5,942 Listeners
391 Listeners
59 Listeners
29 Listeners
5,462 Listeners
147 Listeners
18 Listeners
51 Listeners
371 Listeners